Last Updated : December 17, 2024
Details
FilesGeneric Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Advanced or metastatic malignant pleural mesothelioma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0387-000
Call for patient/clinician input closed:
Tumour Type:
Other
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Keytruda in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult and pediatric (12 years and older) patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Keytruda in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult and pediatric (12 years and older) patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | October 17, 2024 |
|---|---|
| Call for patient/clinician input closed | December 06, 2024 |
| Submission received | November 27, 2024 |
| Submission accepted | December 11, 2024 |
| Review initiated | December 12, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | March 24, 2025 |
| Deadline for sponsors comments | April 02, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | May 02, 2025 |
| Expert committee meeting (initial) | May 14, 2025 |
| Draft recommendation issued to sponsor | May 27, 2025 To May 29, 2025 |
| Draft recommendation posted for stakeholder feedback | June 05, 2025 |
| End of feedback period | June 19, 2025 |
Files
Last Updated : December 17, 2024